Pentobarbital will minimize the extent or outcome of levamlodipine by influencing hepatic/intestinal enzyme CYP3A4 metabolism. pentobarbital will lessen the level or result of lumefantrine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated. Coadministration with sturdy CYP3A4 inducers can lead to lessened serum concentrations and loss of antimalarial efficacy pe... https://lestern010nzn5.jts-blog.com/profile